Black Diamond Therapeutic... (BDTX)
NASDAQ: BDTX
· Real-Time Price · USD
1.65
-0.04 (-2.37%)
At close: May 09, 2025, 3:59 PM
1.70
3.34%
After-hours: May 09, 2025, 05:44 PM EDT
-2.37% (1D)
| Bid | 1.61 |
| Market Cap | 93.23M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -69.68M |
| EPS (ttm) | -1.27 |
| PE Ratio (ttm) | -1.3 |
| Forward PE | -1.22 |
| Analyst | Buy |
| Ask | 1.76 |
| Volume | 554,910 |
| Avg. Volume (20D) | 3,264,555 |
| Open | 1.70 |
| Previous Close | 1.69 |
| Day's Range | 1.61 - 1.73 |
| 52-Week Range | 1.20 - 7.38 |
| Beta | 2.64 |
About BDTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol BDTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for BDTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Black Diamond Therapeutics Inc. is scheduled to release its earnings on May 20, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+2.38%
Black Diamond Therapeutics shares are trading high...
Unlock content with
Pro Subscription
7 months ago
-5.46%
Black Diamond Therapeutics shares are trading higher after the company announced initial Phase 2 data demonstrating encouraging clinical responses and durability of BDTX-1535 in patients with relapsed/refractory epidermal growth factor receptor-mutant non-small cell lung cancer.
